Faes FarmaFRA:FFEA -0.44%90 EBITDA Margin % is 14.85% as of Dec. 2025, which is 41% below its 10-year median of 25.16. GuruFocus rates FRA:FFEA with a GF Score™ of 90/100 and a GF Value™ of €5.02 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Faes Farma ranks better than 67.02% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Faes Farma's EBITDA for the
six
months ended in Dec. 2025 was €46.7 Mil. Faes Farma's Revenue for the
six
months ended in Dec. 2025 was €314.3 Mil. Therefore, Faes Farma's EBITDA margin for the quarter that ended in Dec. 2025 was 14.85%.
Faes Farma (FRA:FFEA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Faes Farma EBITDA Margin % Related Terms
Faes Farma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Faes Farma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:FFEA vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Faes Farma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Faes Farma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Faes Farma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Faes Farma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Faes Farma (FRA:FFEA) has a EBITDA Margin % of 14.85% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Faes Farma and its competitors. This is 41% below median its historical median of 25.16. Over the past decade, Faes Farma's EBITDA Margin % has ranged from 19.71 to 27.71. According to the industry distribution chart, Faes Farma ranks #314 out of 952 companies in the Drug Manufacturers industry, placing it in the top 33%.
Is Faes Farma's EBITDA Margin % too high?
Faes Farma's current EBITDA Margin % of 14.85% is 41% below median its 10-year median of 25.16. Over the past 10 years, this metric has ranged from a low of 19.71 to a high of 27.71. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Faes Farma's value of 14.85% is 19.1% above this industry median. Based on the distribution chart, Faes Farma ranks #314 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Faes Farma has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Faes Farma's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Faes Farma ranks #314 out of 952 companies for EBITDA Margin %. This puts Faes Farma in the upper half of its industry. The industry median EBITDA Margin % is 12.47. Faes Farma's value of 14.85% is 19.1% above this benchmark. Historically, Faes Farma's own EBITDA Margin % has ranged from 19.71 to 27.71 over the past decade. While the company's 10-year median is 25.16 vs. the industry median of 12.47, Faes Farma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Faes Farma's current EBITDA Margin % of 14.85% is 19.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Faes Farma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Faes Farma's current EBITDA Margin % is 14.85%, which is 41% below median its own 10-year median of 25.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faes Farma stock overvalued right now?
Based on GuruFocus' analysis, Faes Farma (FRA:FFEA) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.02, compared to a current price of €4.54 — trading 9.7% below its estimated fair value. The current EBITDA Margin % is 14.85%, which is 41% below median its 10-year median of 25.16 and 19.1% above the Drug Manufacturers industry median of 12.47. Faes Farma's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Faes Farma (FRA:FFEA), the current EBITDA Margin % is 14.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Faes Farma (FRA:FFEA) Overvalued in 2026?
Based on GuruFocus' analysis, Faes Farma stock appears to be undervalued.
The current stock price of €4.54 is trading 9.7% below its estimated GF Value™ of €5.02.
GuruFocus considers Faes Farma to be Modestly Undervalued.
Key valuation signals for FRA:FFEA:
EBITDA Margin %: 14.85% (41% below median its 10-year median of 25.16)
GF Value™: €5.02 vs. price of €4.54 (9.7% below fair value)
Industry Position: 19.1% above the Drug Manufacturers median (#314 of 952)
No single metric tells the full story. See the FRA:FFEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Faes Farma SA purpose is manufacturing and selling all kinds of chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. It is mainly engaged in the manufacture and sale of pharmaceutical products, as well as in the manufacture and sale of animal nutrition and health products. Its segments are Pharmaceutical and healthcare specialities, Animal nutrition and health, and Other segments. It generates majority of revenue from Pharmaceutical and healthcare specialities. It operates mainly in domestic and international markets.
90GF Score
Get the complete analysis for FRA:FFEA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FFEA has been successfully added to your 
